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Introduction: Long-term ketamine abuse may cause variable lower urinary tract symptoms (LUTS) and
severe cystitis. The clinical features of ketamine-associated cystitis (KC) are very similar to bladder pain
syndrome/interstitial cystitis (BPS/IC). Intravesical administration of hyaluronic acid (HA) is one of the
regimens for treating BPS/IC. In this study, we aim to investigate whether intravesical HA therapy may
improve the LUTS of patients with KC.
Materials and methods: Four female patients and one male patient with KC who failed oral medications
were enrolled in this study. HA (Cystistat) at a dose of 40 mg in a volume of 50 mL of phosphate-buffered
saline was injected into the bladder on a weekly basis for 6 weeks and then monthly for a further 3
months. Response to therapy was evaluated by the visual analog scale (VAS) for pain, International
Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS), O'Leary-Sant Interstitial
Cystitis Symptom Index (ICSI), and Interstitial Cystitis Problem Index (ICPI). Treatment efﬁcacy was
assessed by comparing the pretreatment and posttreatment mean scores of the ﬁve questionnaires using
the paired t test.
Results: The mean age of the patients was 22 ± 1.5 years. The mean duration of ketamine abuse was
68 ± 16.7 months. After intravesical HA therapy for 4 weeks, statistically signiﬁcant mean decreases in
VAS (from 7 to 4.4, p ¼ 0.03), IPSS voiding subscore (from 16.2 to 11.6, p ¼ 0.017), and ICSI (from 16.4 to
13.6, p ¼ 0.016) questionnaire scores were seen. However, only ICSI constantly reduced after 4 weeks of
treatment.
Conclusion: Intravesical HA therapy may have short-term beneﬁts for improving bladder pain and
voiding symptoms in patients with KC.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ketamine is a phencyclidine derivative which was ﬁrst used in
humans in 1965, and has been clinically used as a quick-acting
anesthetic drug since the 1970s.1 Its receptor binding has not
been fully elucidated but includes an antagonist action at N-
methyl-D-aspartate receptors throughout the central and pe-
ripheral nervous system. Ketamine is recently becoming more
widely used as a recreational drug, especially in night clubs and
dance parties.2 Many young people start using ketamine astment of Surgery, Tri-Service
d, Neihu District, 114, Taipei,
ociation. Published by Elsevier Tateenagers. The precise prevalence of recreational, nonmedical
ketamine use is unknown. A recent government report in Taiwan
has indicated that the percentage of ketamine increased
dramatically in the past few years, making it one of the most
popular drugs of investigation ﬁndings.3 A recent study assessing
the prevalence of urinary symptoms in a large cohort of
nontreatment-seeking ketamine users revealed that 26.6% of
recent ketamine users experienced urinary symptoms. Urinary
symptoms were signiﬁcantly related to both dose of ketamine
used and frequency of ketamine use.4
The symptoms of ketamine-associated cystitis (KC) include a
variety of lower urinary tract symptoms (LUTS) which are very
similar to bladder pain syndrome/interstitial cystitis (BPS/IC).
Typically, the patients complain of nocturia, urgency, extreme fre-
quency, bladder pain, and intractable dysuria. Gross hematuria isiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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Tsai et al6 reported that although symptoms appeared after 1
month of starting the usage, they became severe after 1 year.
The pathogenesis of bladder dysfunction under this condition
has still not been established. A recent pathological research on
the urinary bladder of ketamine addiction employing mice re-
veals mononuclear inﬁltration, very similar to that of the clinical
situation of BPS/IC. There was also a possible decrease in the
cholinergic neurons in the urinary bladder of the ketamine-
treated animals.7 A mouse model of ketamine abuse showed
that dysregulation of purinergic neurotransmission may be the
cause of detrusor overactivity in ketamine-induced bladder
dysfunction.8
The goal of treatment is to prevent deterioration of the renal
function and indeed offer the possibility of symptom resolution.
Currently, ketamine cessation is the only effective treatment mo-
dality, but the effect is likely to be dependent on the severity and
duration of the abuse.5,6,9 Patient compliance has previously been
shown to be poor in patients suffering addiction and failure to
abstain may lead to disease progression.5,10 Various treatment
regimens have been used to treat the patients such as antibiotics,
oral NSAIDS, steroids, anticholinergic therapy,5 and hydro-
distention of the bladder,6 however, all have failed to provide sig-
niﬁcant and lasting improvement.
Since the clinical features of KC are very similar to BPS/IC, the
possible etiology of impaired epithelial impermeability leading to
leakage of glycosaminoglycan (GAG) layer has led to the use of
intravesical instillation of hyaluronic acid (HA) in the treatment of
IC. Tsai et al6 reported that all patients who had HA instillation had
symptomatic relief, especially in bladder pain, frequency, and
hematuria, however no convincing evidence has been provided in
this article. In this study, we aim to investigate the efﬁcacy of
intravesical instillation of HA in the treatment of KC.2. Materials and methods
Patients (18 years of age) attending the Tri-Service General
Hospital, Taipei, Taiwan for treatment of symptoms of KC were
recruited for this open, prospective, unblinded, uncontrolled study.
The study was approved by the Institutional Review Board of the
Tri-Service General Hospital, Taipei, Taiwan (TSGH- 100-05-188)
and all patients gave their written informed consent before
participating in the study. Eligible patients had a  6-month
documented history of KC. The diagnosis of KC was made accord-
ing to their history and clinical features. Other common causes of
LUTS, such as urinary tract infection, urological malignancy,
bladder outlet obstruction, neurological disease, or trauma were
excluded. Careful history taking of ketamine use, including mean
dose usage/d, duration of drug abuse, and the route of use, was
performed by one urologist with conﬁdential interviews. Physical
examinations and assessment of symptoms were performed in all
patients in an outpatient department. Urinary cultures, urinary
cytology, and acid-fast stain for urinary tuberculosis were
completed in enrolled patients to exclude other possible causes.
Before any treatment was initiated, urodynamic investigations
were conducted mainly on an outpatient basis. A standard uro-
ﬂowmetry was performed before pressure ﬂow studies. Postvoid-
ing residual urine was measured by urethral catheterization. The
pressure ﬂow studies were performed according to the ICS stan-
dardization.9 After the urodynamic studies, cystoscopy under spi-
nal anesthesia with hydrodistention and a biopsy of the bladder
wall was performed to conﬁrm the diagnosis. Maximum bladder
capacity under spinal anesthesia was measured before hydro-
distention, using an infusion height of 80 cm above the symphysispubis, and the amount when the bladder had been ﬁlled and ﬂuid
had stopped dribbling from a dripping chamber was recorded.
Patients were excluded from the study if they were pregnant,
had received another medical or mechanical treatment for KC
(excluding pain treatment) 1 month prior to screening, or if they
had a known sensitivity to any component of the HA preparation
used for bladder instillation. Over the study period, no other
treatments for KC were permitted, besides analgesics. Before each
HA instillation, every patient received a urine screening test using a
direct enzyme-linked immunosorbent assay kit for ketamine
(Firstep Bioresearch, Inc., Tainan, Taiwan) and the patients with a
positive result were withdrawn from the study.
Eligible patients received intravesical instillations of HA
(Cystistat; Bioniche Life Sciences Inc., Belleville, ON, Canada) at a
dose of 40 mg in a volume of 50 mL of phosphate-buffered sa-
line. The intravesical instillation was performed using a catheter,
under sterile conditions, after the removal of residual urine.
Following the instillation, patients were asked to retain the HA
in their bladders for as long as possible, with a minimum
retention time of 30 minutes. HA acid was administered to all
patients once weekly for 6 weeks (Day 0, Day 7, Day 14, Day 21,
Day 28, and Day 35) and then once monthly for 3 months (total
of 9 instillations).
Response to therapy was assessed using a questionnaire
administered to all patients at baseline and at each hospital visit.
The questionnaire assessed O'Leary-Sant Interstitial Cystitis
Symptom Index (ICSI), Interstitial Cystitis Problem Index (ICPI),
International Prostate Symptom Score (IPSS), Overactive Bladder
Symptom Score (OABSS), and use of analgesics since the last visit.
In addition, the level of pain was assessed at each visit using a
visual analog scale (VAS; 10-point scale). To assist in recording the
information, all patients were given a diary and asked to record
relevant symptoms between visits. This diary then served as an
information source during the administration of the question-
naire. The questionnaire also asked the patients to record how
long they had retained the HA solution in their bladders after each
instillation.
Continuous variables are analyzed with the paired t test. A p
value < 0.05 is considered statistically signiﬁcant.
3. Results
Nine patients were recruited for the study and four of them
were withdrawn due to being unable to tolerate the catheteriza-
tion. Only ﬁve patients completed the whole course of treatment
(Table 1). The mean age (±standard deviation) of the patients was
22 ± 1.5 years. The mean duration of ketamine abuse was 68 ± 16.7
months.
There was a large variation in the time for which patients were
capable of keeping the HA solution in the bladder (Fig. 1). The mean
time of keeping HA in the bladder seemed to have a trend of being
longer in the ﬁrst 4 weeks (from 46.4 ± 52.6 minutes to 76.4 ± 65.5
minutes), although there was no signiﬁcant difference. There was
no correlation between the efﬁcacy of HA and the time for which
the solution was retained in the bladder.
Table 2 shows change in scores of the ﬁve questionnaires in ﬁve
patients receiving intravesical HA treatment. After intravesical
treatment of HA for 4 weeks, statistically signiﬁcant mean de-
creases in VAS (from 7.0 ± 2.2 to 4.4 ± 0.6, p ¼ 0.03), IPSS voiding
subscore (from 16.2 ± 3.8 to 11.6 ± 4.2, p ¼ 0.017), and ICSI (from
16.4 ± 2.7 to 13.6 ± 2.0; p ¼ 0.016) questionnaire scores were seen.
However, only ICSI constantly reduced after 4 weeks of treatment
until the 14th week. No signiﬁcant changes were seen before and
after treatment in OABSS questionnaire values. No cases of side
effects or complications were observed.
Table 1
Patient characteristics and urodynamic data.
No. Sex Age Dose (g/d) Duration of ketamine abuse (mo) FBC (mL) MBC (mL)
1 Female 25 1e5 84 41 100
2 Female 21 1e5 54 14 120
3 Female 21 1e5 72 146 250
4 Female 24 1e5 84 255 500
5 Male 21 6e10 48 75 150
FBC ¼ functional bladder capacity; MBC ¼ maximal bladder capacity under anesthesia.
Fig. 1. The mean duration of keeping hyaluronic acid in the bladder.
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KC is a new disease entity and its clinical features are very
similar to BPS/IC.5 Intravesical HA instillation has been used to treat
BPS/IC with a good symptom response rate.11,12 However, the
treatment strategy of KC is to be established. In this study, we
investigate the therapeutic effect of intravesical HA instillation in
patients with KC. The results showed that HA instillation may
temporarily reduce the pain and improve voiding symptoms
associated with KC after 4 weeks of treatment. Intravesical instil-
lation of HA on a monthly basis may not be as effective as on a
weekly basis. However, large, long-term randomized studies are
required to determine if there is a long-term efﬁcacy of intravesical
hyaluronan therapy in KC.
Long-term ketamine abuse can cause severe cystitis and LUTS.
Cystoscopy reveals various degrees of epithelial inﬂammation andTable 2
Change in scores of questionnaires after hyaluronic acid (HA) treatment (mean ± standa
Time after HA treatment 0 (Baseline) 1 wk 2 wk 3 wk 4
VAS 7.0 ± 2.2 6.4 ± 2.7 5.4 ± 1.9 5.0 ± 2.2
Change from baseline 0.60 ± 1.8 1.6 ± 2.5 2.0 ± 3.2 
IPSS 28.8 ± 4.8 26.4 ± 3.1 26.2 ± 4.1 25.2 ± 5.3 2
Change from baseline 2.4 ± 5.8 2.6 ± 4.4 3.6 ± 4.9 
IPSS-V 16.2 ± 3.8 13.4 ± 1.8 14.0 ± 4.3 13.6 ± 4.7 1
Change from baseline 2.8 ± 3.6 2.2 ± 3.3 2.6 ± 3.2 
IPSS-S 12.0 ± 2.4 11.6 ± 2.3 11.2 ± 1.9 10.8 ± 1.9 1
Change from baseline 0.40 ± 2.5 0.40 ± 1.7 1.0 ± 1.9 
OABSS 11 ± 2.7 9.4 ± 2.8 10 ± 2.9 8.8 ± 2.5
Change from baseline 1.8 ± 1.8 0.80 ± 0.8 2.4 ± 1.9 
ICSI 16.4 ± 2.7 14.4 ± 2.1 14.8 ± 3.0 13.4 ± 2.3 1
Change from baseline 2.0 ± 1.4 1.6 ± 1.1 3.0 ± 1.6* 
ICPI 14.2 ± 2.2 12.0 ± 2.6 13.0 ± 3.3 12.6 ± 4.0 1
Change from baseline 2.2 ± 1.9 1.2 ± 1.6 1.6 ± 2.5 
*p < 0.05.
**p < 0.05.
ICPI ¼ Interstitial Cystitis Problem Index; ICSI ¼ Interstitial Cystitis Symptom Index; IPS
Score; VAS ¼ visual analog scale.
a The p value was determined using paired t test. The p value refers to the comparison
acid treatment.neovascularization of the bladder with KC. The urothelium is
particularly fragile and easily denuded, indicating a defective
connection to the lamina propria. Severe cases may present pete-
chial hemorrhages and ulcers of the bladder mucosa, as classically
described in patients with IC.5 Abnormal expression of GAG-related
proteinsdchondroitin sulfate, perlecan, biglycan, decorin,
syndecan-1, uroplakin, E-cadherin, keratin 18, and keratin 20, as
well as the tight-junction-associated protein ZO-1dseems to be
associated with BPS/IC.13 GAG derivatives are therefore used as
substitutes for components of the GAG layer of the urothelial lining,
which is severely damaged in BPS/IC.13 Hyaluronan may reinforce
the urine-tissue barrier by integration in the GAG layer on the
luminal surface and the base of urothelial cells; it also has unique
antiinﬂammatory mechanisms, like inhibition of leukocyte migra-
tion, adherence of immune complexes, and binding to speciﬁc re-
ceptors (Intercellular Adhesion Molecule 1, ICAM-1; Cluster of
Differentiation 44, CD 44) involved in the inﬂammatory
process.14e16
The use of HA instillations in treating BPS/IC is supported by
several studies with level 2b evidence, although some researchers
questioned its efﬁcacy.17 Monotherapy with HA (4-weekly 1 mg/mL
in saline, followed by 2-monthly instillations) has been reported to
produce response rates of 30e85%.11,12,18e21 In our study, we per-
formed HA treatment after hydrodistention. A randomized
controlled trial examined the use of HA after hydrodistention, and
the researchers found prolonged symptom improvement with HA
treatment and hydrodistention compared with hydrodistention
alone in 78% of patients.22
Our instillation protocol was once weekly in intravesical in-
stillations of HA for 6 weeks and three more instillations were
performed monthly. This protocol was similar to that of other
groups. In the literature, several different protocols have beenrd deviation).a
wk 5 wk 6 wk 10 wk 14 wk 18 wk
4.4 ± 0.6 4.6 ± 1.9 3.6 ± 1.1 4.4 ± 3.6 3.8 ± 1.8 3.3 ± 2.1
2.6 ± 1.8* 2.4 ± 3.5 3.4 ± 2.7* 2.6 ± 4.7 3.2 ± 3.4 4.2 ± 2.7
2.4 ± 4.3 23.2 ± 4.6 22.8 ± 3.3 23.2 ± 3.1 22.6 ± 6.1 20.0 ± 6.0
6.4 ± 3.2 5.6 ± 3.8 6.0 ± 4.5 5.6 ± 3.1 6.2 ± 6.8 7.8 ± 8.2
1.6 ± 4.2 12.4 ± 4.7 12.0 ± 3.9 12.8 ± 4.4 11.8 ± 5.1 10.3 ± 3.2
4.6 ± 2.6* 3.8 ± 2.9 4.2 ± 3.0 3.4 ± 3.2 4.4 ± 4.3 4.5 ± 4.5
0.6 ± 1.7 10.0 ± 2.5 10.0 ± 1.9 8.8 ± 3.0 9.2 ± 3.6 9.7 ± 4.0
1.8 ± 1.3 1.8 ± 1.6 1.8 ± 2.3 2.2 ± 2.2 1.8 ± 3.1 2.0 ± 4.8
9.2 ± 1.6 8.6 ± 2.7 8.4 ± 2.5 8.2 ± 3.3 7.2 ± 2.9 7.5 ± 2.4
2.0 ± 2.7 2.6 ± 1.5 2.8 ± 3.6 3.0 ± 2.9 4.0 ± 1.0 3.0 ± 2.4
3.6 ± 2.0 12.2 ± 2.2 12.6 ± 2.1 12.4 ± 3.4 11.8 ± 2.7 13.5 ± 1.3
2.8 ± 1.5* 4.2 ± 2.4* 3.8 ± 2.2* 4.0 ± 1.4** 4.6 ± 3.4* 1.5 ± 3.9
1.8 ± 3.8 12.4 ± 3.6 12.4 ± 3.8 12.4 ± 3.5 11.4 ± 2.9 11.7 ± 4.5
2.4 ± 2.9 1.8 ± 2.2 1.8 ± 2.7 1.8 ± 2.5 2.8 ± 2.4 2.8 ± 2.5
S ¼ International Prostate Symptom Score; OABSS ¼ Overactive Bladder Symptom
of scores of questionnaires between baseline and indicated weeks after hyaluronic
E. Meng et al. / Urological Science 26 (2015) 176e179 179described for instillation. Many uncontrolled studies used 40 mg
HA dissolved in 40 mL of normal saline solution weekly for 4e6
weeks and then monthly.19,23,24
In the present study, improvements regarding the VAS for pain,
voiding symptoms, and ICSI were statistically signiﬁcant after 4
weeks of treatment compared with the respective baseline values.
However, there was no signiﬁcant improvement in the storage
symptoms and ICPI. Only ICSI constantly reduced after 6 weeks of
treatment. The result suggests that intravesical HA instillation may
temporarily relieve voiding symptoms and pain caused by KC.
The relatively poor response of intravesical HA instillation in
treating KC may be due to: (1) KC has been reported as a severe
form of BPS/IC25 and the damage to the urothelium may be more
difﬁcult to repair than in BPS/IC; (2) monotherapy with HA used in
the present study may not be as effective as combination intra-
vesical therapy using both sodiumHA and chondroitin sulfate26e28;
and (3) young patients have poor tolerance to intravesical HA
instillation and are not able to keep HA in the bladder for a long
time.
The present ﬁndings give hope to KC patients that are suffering
from the diagnosis of a chronic and incurable disease. However, this
study has some limitations which are mainly represented by the
small sample size, the short follow up, and the lack of a placebo
control group. Although a randomized, placebo-controlled study is
necessary to further conﬁrm efﬁcacy of HA instillation for KC pa-
tients, we felt that an randomized controlled trial (RCT) design,
where patients would be randomized to no treatment or placebo,
may be difﬁcult, as these patients were in severe pain and were
desperate for treatment.
5. Conclusion
In spite of the small number of patients included in this study,
there is evidence to indicate that intravesical HA therapy has a
short-term positive impact on the treatment of KC. The therapy
may reduce pain and improve voiding symptoms associated with
KC after 4 weeks of HA instillation. Large, long-term randomized
studies are required to determine if there is a long-term efﬁcacy of
intravesical HA therapy in KC.
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